Bart Barlogie

Summary

Affiliation: University of Arkansas for Medical Sciences
Country: USA

Publications

  1. ncbi request reprint Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, USA
    Leuk Lymphoma 43:1267-71. 2002
  2. ncbi request reprint Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience
    Bart Barlogie
    University of Arkansas for Medical Sciences, 4301 W Markham, Slot 623, Little Rock, AR 72205, USA
    Semin Hematol 40:33-8. 2003
  3. pmc Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
    Xenofon Papanikolaou
    Myeloma Institute for Research and Therapy, Little Rock, AR, USA
    Haematologica 98:1147-53. 2013
  4. pmc Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
    Sarah Waheed
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Haematologica 98:71-8. 2013
  5. ncbi request reprint Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
    Bart Barlogie
    Medicine and Pathology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 107:2633-8. 2006
  6. pmc Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3115-21. 2008
  7. doi request reprint Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 113:355-9. 2008
  8. doi request reprint Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 112:2720-5. 2008
  9. ncbi request reprint Treatment of multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 103:20-32. 2004
  10. pmc Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR 72205, USA
    Blood 111:94-100. 2008

Collaborators

Detail Information

Publications111 found, 100 shown here

  1. ncbi request reprint Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, USA
    Leuk Lymphoma 43:1267-71. 2002
    ..The use of thalidomide should be carefully assessed in relapsed multiple myeloma patients with clinical and cytogenetic evidence of t-MDS...
  2. ncbi request reprint Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience
    Bart Barlogie
    University of Arkansas for Medical Sciences, 4301 W Markham, Slot 623, Little Rock, AR 72205, USA
    Semin Hematol 40:33-8. 2003
    ..These preliminary results corroborate the role for thalidomide and CC-5013 in relapsed/refractory and newly diagnosed multiple myeloma based on the UAMS phase II study as well as several other studies of these agents outside of UAMS...
  3. pmc Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
    Xenofon Papanikolaou
    Myeloma Institute for Research and Therapy, Little Rock, AR, USA
    Haematologica 98:1147-53. 2013
    ..In conclusion, metronomic therapy is an effective late salvage treatment in relapsed/refractory multiple myeloma, with a high overall response rate and a favorable toxicity profile...
  4. pmc Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
    Sarah Waheed
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Haematologica 98:71-8. 2013
    ..Clinicaltrials.gov identifier: NCT00081939)...
  5. ncbi request reprint Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
    Bart Barlogie
    Medicine and Pathology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 107:2633-8. 2006
    ..The favorable effects of CR and rapidly sequenced second transplantation attest to the validity of a melphalan dose-response effect in myeloma...
  6. pmc Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3115-21. 2008
    ..008). Because two thirds of patients without CAs have remained alive at 7 years, the presently emerging separation in favor of thalidomide may eventually reach statistical significance as well...
  7. doi request reprint Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 113:355-9. 2008
    ..Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma...
  8. doi request reprint Completion of premaintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma: an important variable to be considered in clinical trial designs
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 112:2720-5. 2008
    ..Total Therapy (TT) programs are complex and their execution over the course of several years is fraught with patient attrition due to failure and toxicity of therapy and patient/physician acceptance...
  9. ncbi request reprint Treatment of multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 103:20-32. 2004
    ..Fundamental and clinical research should, therefore, focus on the molecular and biologic mechanisms of treatment failure in the high-risk subgroup...
  10. pmc Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR 72205, USA
    Blood 111:94-100. 2008
    ..While the risk of MDS-CAs was low and clinical MDS occurred infrequently, monitoring after post-HDT consolidation chemotherapy appears warranted...
  11. ncbi request reprint Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma Myeloma 6:469-74. 2006
    ..Complete response has been considered a surrogate for favorable long-term outcome in multiple myeloma. Data on the impact of the duration of response on prognosis are lacking...
  12. ncbi request reprint Thalidomide and hematopoietic-cell transplantation for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    N Engl J Med 354:1021-30. 2006
    ..High-dose therapy with melphalan can prolong survival among patients with multiple myeloma. We assessed whether the addition of thalidomide, which has activity against advanced and refractory myeloma, would further improve survival...
  13. pmc The Arkansas approach to therapy of patients with multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, UAMS, Little Rock, AR, USA
    Best Pract Res Clin Haematol 20:761-81. 2007
    ....
  14. pmc Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Clin Oncol 28:3023-7. 2010
    ..After further follow-up of 87 months, we examined, in reiterative analyses, the effect of increasing time intervals on clinical outcomes relevant to baseline prognostic variables and treatment randomization...
  15. pmc Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham, 816, Little Rock, AR 72205
    J Clin Oncol 28:1209-14. 2010
    ....
  16. pmc Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham 816, Little Rock, AR 72205, USA
    Ann Hematol 90:423-8. 2011
    ..Our observations of LM dependency of PF can be exploited toward advancing myeloma therapy by stratifying patients according to whether early or late portions of the survival history are being targeted...
  17. ncbi request reprint Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Exp Hematol 31:73-80. 2003
    ..The aim of this study was to identify prognostic factors for outcome of high-risk patients with multiple myeloma after allogeneic transplantation prepared by reduced intensity conditioning (RIC)...
  18. pmc High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 112:1754-64. 2008
    ..In this report, the authors describe their collective experience with melphalan-based autotransplants since the inception of their program at the University of Arkansas for Medical Sciences in 1989...
  19. ncbi request reprint Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 138:176-85. 2007
    ..Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients...
  20. pmc Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
    Lijuan Chen
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 115:61-70. 2010
    ..Consistently, JUN or EGR-1 knockdown in cultured MM cells enhanced their resistance to bortezomib, demonstrating the crucial role of low JUN/EGR-1 expression in MM resistance to bortezomib...
  21. ncbi request reprint DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma
    Choon Kee Lee
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Slot 776, 4301 West Markham, Little Rock, AR 72205, USA
    J Clin Oncol 21:2732-9. 2003
    ..To improve outcome in previously treated patients (at least two cycles of standard therapy) with multiple myeloma, thalidomide was combined with cytotoxic chemotherapy as induction therapy...
  22. ncbi request reprint Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 136:393-9. 2007
    ..In comparison with U-MM, E-MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U-MM...
  23. doi request reprint NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
    Sathisha Upparahalli Venkateshaiah
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Exp Hematol 41:547-557.e2. 2013
    ..These findings indicate that MM cells and osteoclasts are highly sensitive to NAD(+) depletion and that PBEF1 inhibition represents a novel approach to target cellular metabolism and inhibit PARP-1 and bone disease in MM...
  24. pmc High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2
    Yiming Zhou
    Donna D and Donald M Lambert Laboratory for Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Proc Natl Acad Sci U S A 107:7904-9. 2010
    ..Silencing of AGO2 dramatically decreased viability in MM cell lines. Genome-wide elevated expression of miRNAs in high-risk MM may be secondary to deregulation of AGO2 and the enzyme complexes that regulate miRNA maturation and function...
  25. ncbi request reprint Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Clin Lymphoma 4:32-5. 2003
    ..001). However, the development of DVT did not adversely affect survival when examined as a time-dependent variable and adjusted for standard risk features (hazard ratio, 0.8; P = 0.162)...
  26. pmc Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA
    Blood 112:3122-5. 2008
    ..Trial registered at http://www.clinicaltrials.gov under identifier NCT00083382...
  27. pmc Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 145:775-87. 2009
    ..These data demonstrated that DASH proteases are involved in myeloma bone disease and tumour growth...
  28. pmc Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival
    Bijay Nair
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Blood 113:6572-5. 2009
    ..001). Based on its PRS predictive power, GEP analysis should be an integral part of new agent trials in search of better therapy for high-risk myeloma...
  29. ncbi request reprint Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival
    Yun Ge
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 133:83-92. 2006
    ..Our results indicate that FAP is critical for the interaction of MM cells with the BM microenvironment--a potential therapeutic target in myeloma...
  30. pmc International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols
    Sarah Waheed
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cancer 117:1001-9. 2011
    ....
  31. pmc Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 116:1220-7. 2010
    ....
  32. pmc Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
    Bijay Nair
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 115:4168-73. 2010
    ..The robustness of the GEP risk model should be exploited in clinical trials aimed at improving the notoriously poor outcome in high-risk disease...
  33. ncbi request reprint Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
    John Shaughnessy
    Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 120:44-52. 2003
    ..02 and 0.1 respectively) and should be part of the initial work-up of patients with MM...
  34. pmc Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
    Ya Wei Qiang
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:196-207. 2008
    ....
  35. pmc Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 121:1819-23. 2013
    ..This trial was registered at www.clinicaltrials.gov as #NCT00081939 and # NCT00572169...
  36. ncbi request reprint Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications
    Ronald Walker
    Department of Radiology, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Clin Oncol 25:1121-8. 2007
    ..Magnetic resonance imaging (MRI) permits the detection of diffuse and focal bone marrow infiltration in the absence of osteopenia or focal osteolysis on standard metastatic bone surveys (MBSs)...
  37. pmc Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
    Mauricio Pineda-Roman
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 140:625-34. 2008
    ..Our data strongly suggest that the addition of bortezomib in TT3 was accountable for its superior performance rather than greater compliance with protocol completion as a result of greater dose-density in TT3 vs. TT2...
  38. pmc F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
    Twyla B Bartel
    Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 114:2068-76. 2009
    ..Our results provide a rationale for testing the hypothesis that myeloma survival can be improved by altering treatment in patients in whom FDG suppression cannot be achieved after induction therapy...
  39. pmc RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma
    Siqing Wang
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR, USA
    Blood 114:600-7. 2009
    ..These findings provide a rationale for RA-based therapy in aggressive RARalpha2(+) MM...
  40. pmc Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Blood 121:4753-7. 2013
    ..Thus, treatment, host, and myeloma features could be linked to MDS development after therapy for this malignancy. This trial was registered at www.clinicaltrials.gov: TT3A: NCT00081939, TT3B: NCT00572169...
  41. pmc Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 109:1692-700. 2007
    ..01). The MGUS-L signature was also seen in plasma cells from 15 of 20 patients surviving more than 10 years after autotransplantation. These data provide insight into the molecular mechanisms of plasma-cell dyscrasias...
  42. ncbi request reprint Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics
    John D Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 137:530-6. 2007
    ....
  43. pmc Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile
    Yiming Zhou
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 West Markham 816, Little Rock, AR 72205, USA
    Br J Haematol 145:637-41. 2009
    ..42, P = 0.004). The prevalence of high-risk myeloma in the RS+/FL+ group may reflect a dissemination-prone condition not shared by the other three groups...
  44. ncbi request reprint Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321
    Bart Barlogie
    University of Arkansas for Medical Science, Little Rock, AR, USA
    J Clin Oncol 24:929-36. 2006
    ....
  45. ncbi request reprint Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 119:164-8. 2002
    ..Other approaches may be required to improve survival in multiple myeloma...
  46. pmc Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantatio
    Ichiro Hanamura
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St 776, Little Rock, AR 72205, USA
    Blood 108:1724-32. 2006
    ..027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis...
  47. pmc TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
    John D Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 147:347-51. 2009
    ..FGFR3+ and FGFR3- molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol-, genome-defined risk- and molecular subgroup-dependent...
  48. ncbi request reprint Long-term outcome results of the first tandem autotransplant trial for multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Br J Haematol 135:158-64. 2006
    ..038). Ten-year EFS and OS could be accomplished in 15% and 33% of patients, respectively, when all agents available in 1989, especially high-dose melphalan, were applied together upfront for the management of myeloma...
  49. pmc The molecular classification of multiple myeloma
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 108:2020-8. 2006
    ..A subset of cases with a predominating myeloid gene expression signature, excluded from the profiling analyses, had more favorable baseline characteristics and superior prognosis to those lacking this signature...
  50. ncbi request reprint A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
    John D Shaughnessy
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2276-84. 2007
    ..Our data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions...
  51. ncbi request reprint Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 118:1041-7. 2002
    ..Furthermore, these parameters in combination with easily obtained pretransplant levels of beta-2 microglobulin and albumin define three groups of MM patients with clearly distinct outcomes...
  52. pmc Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3
    John D Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock AR, USA
    Blood 118:3512-24. 2011
    ..We are investigating whether second-generation proteasome inhibitors (eg, carfilzomib) can overcome resistance associated with high PSMD4 levels...
  53. ncbi request reprint Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy
    Giampaolo Talamo
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Clin Oncol 23:5217-23. 2005
    ..To assess the prevalence, time of onset, risk factors, and outcome of avascular necrosis (AVN) of bone in patients with multiple myeloma undergoing antineoplastic therapy...
  54. doi request reprint Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis
    Elias J Anaissie
    Myeloma Institute for Research and Therapy, Division of Supportive Care, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Cancer 118:549-57. 2012
    ..As a result, most patients receive thromboprophylaxis with low molecular weight heparin (LMWH). The purpose of this retrospective study was to identify risk factors for VTE in NDMM and evaluate the effectiveness of LMWH...
  55. pmc Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
    Frits van Rhee
    University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock AR 72205, USA
    Mol Cancer Ther 8:2616-24. 2009
    ....
  56. pmc Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 141:433-44. 2008
    ..These results provide a basis for the prospective evaluation of the consolidation strategy in a randomized clinical trial design...
  57. ncbi request reprint Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience
    Athanasios B T Fassas
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 123:484-9. 2003
    ..In conclusion, a sizeable fraction of myeloma patients relapsing after tandem autotransplants without poor-risk features enjoyed meaningful survival prolongation when appropriately treated...
  58. pmc Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone
    Xin Li
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Stem Cells 29:263-73. 2011
    ..This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis...
  59. ncbi request reprint Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients
    Maurizio Zangari
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Blood Coagul Fibrinolysis 18:595-8. 2007
    ..02). Our observation suggests a possible beneficial effect of anticoagulation on survival in patients treated for myeloma...
  60. pmc First thalidomide clinical trial in multiple myeloma: a decade
    Frits van Rhee
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 112:1035-8. 2008
    ..The poor outcome associated with lambda-type myeloma may relate to its overrepresentation in molecularly defined high-risk disease gleaned from studies in newly diagnosed myeloma...
  61. pmc Prediction of cytogenetic abnormalities with gene expression profiles
    Yiming Zhou
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 119:e148-50. 2012
    ..The model has an accuracy rate up to 0.89. These results provide proof of concept for the hypothesis that gene expression profiling is a superior genomic method for clinical molecular diagnosis and/or prognosis...
  62. ncbi request reprint Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression
    John Shaughnessy
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 101:3849-56. 2003
    ....
  63. pmc Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance
    Saad Z Usmani
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 120:1597-600. 2012
    ..38; P = .09). These trials are registered at www.clinicaltrials.gov as NCT00573391 (TT2), NCT00081939 (TT3A), and NCT00572169 (TT3B)...
  64. ncbi request reprint Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 126:715-21. 2004
    ..The rate of DVT recurrence observed in our study upon thalidomide resumption was sufficiently low to allow its continuation in patients who may benefit from this therapeutic intervention...
  65. ncbi request reprint The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
    Erming Tian
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, College of Medicine, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    N Engl J Med 349:2483-94. 2003
    ..Myeloma cells may secrete factors that affect the function of osteoblasts, osteoclasts, or both...
  66. pmc The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
    Simona Colla
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 109:4470-7. 2007
    ..We conclude that specific strategies to modulate persistent activation of the JNK pathway may be beneficial in preventing disease progression and treating myeloma-associated bone disease by inhibiting DKK1 expression...
  67. pmc Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
    Shmuel Yaccoby
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 109:2106-11. 2007
    ..We conclude that DKK1 is a key player in MM bone disease and that blocking DKK1 activity in myelomatous bones reduces osteolytic bone resorption, increases bone formation, and helps control MM growth...
  68. ncbi request reprint Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen
    Christopher L Morris
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 120:413-23. 2003
    ..Increasing age adversely affected CD34+ yield even with limited premobilization therapy, indicating that early collection is important in elderly patients...
  69. pmc Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling
    Ya Wei Qiang
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 113:4319-30. 2009
    ....
  70. pmc CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham Street, Little Rock, AR 72205, USA
    Blood 109:4995-5001. 2007
    ....
  71. ncbi request reprint Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
    Maurizio Zangari
    The Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 131:71-3. 2005
    ..The rise in ALP after bortezomib in three patients was explained by a parallel increase in bone-specific ALP and parathyroid hormone, suggesting that response to bortezomib in myeloma is closely associated with osteoblastic activation...
  72. ncbi request reprint High-dose therapy and immunomodulatory drugs in multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Semin Oncol 29:26-33. 2002
    ..Careful scrutiny of gene expression will also help in the identification of unrecognized targets for therapeutic intervention...
  73. ncbi request reprint Using genomics to identify high-risk myeloma after autologous stem cell transplantation
    John D Shaughnessy
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Biol Blood Marrow Transplant 12:77-80. 2006
    ..Synergy between cyclin D2 and CKS1B, but not cyclin D1 and CKS1B, may lead to early treatment failure...
  74. doi request reprint Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma
    Erming Tian
    The Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Mol Cancer Ther 7:500-9. 2008
    ..Collectively, our data suggest that EPED3 targets mitochondrial function to rapidly deplete chemical energy and initiate apoptosis in myeloma cells at nanomolar concentrations while leaving stromal cells unharmed...
  75. ncbi request reprint Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development
    Fenghuang Zhan
    Donna and Donald Lambert Laboratory of Myeloma Genetics at the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 101:1128-40. 2003
    ..000 09). MM1 showed no significant linkage with normal cell types studied. Thus, genes whose expression is linked to distinct transitions in late-stage B-cell differentiation can be used to classify MM...
  76. pmc Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204)
    Mohamad A Hussein
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, 4301 W Markham St, 816, Little Rock, AR 72205, USA
    J Clin Oncol 27:3510-7. 2009
    ..CONCLUSION Both overall survival (P = .0002) and event-free survival (P < .0001) were significantly improved with S0204 compared with S9321 when 121 and 363 patients, respectively, were matched on ISS stage and LDH...
  77. ncbi request reprint Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity
    Shmuel Yaccoby
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Br J Haematol 116:278-90. 2002
    ..Breaking this loop may help control myeloma...
  78. ncbi request reprint ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Transfusion 42:205-9. 2002
    ..Blood group incompatibility does not appear to affect the overall outcome in patients undergoing myeloablative conditioning before allogeneic BMT. Data on ABO-mismatched transplantation in the nonmyeloablative setting are limited...
  79. pmc The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth
    Angela Pennisi
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Blood 114:1803-12. 2009
    ..Myeloma cells expressed low to undetectable ephrinB2 and EphB4 and did not respond to the chimeric proteins. The ephrinB2/EphB4 axis is dysregulated in MM, and its activation by EphB4-Fc inhibits myeloma growth and bone disease...
  80. ncbi request reprint The role of transplant in multiple myeloma
    Bart Barlogie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Clin Adv Hematol Oncol 3:604-6. 2005
  81. ncbi request reprint Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
    Fenghuang Zhan
    Donna D and Donald M Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, 72205, USA
    Blood 99:1745-57. 2002
    ..Thus, novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM...
  82. ncbi request reprint Early results of total therapy II in multiple myeloma: implications of cytogenetics and FISH
    Bart Barlogie
    Myeloma Institute for Research and Therapy, USA
    Int J Hematol 76:337-9. 2002
    ..Thus, both cytogenetics and FISH are recommended in the initial evaluation of patients with MM...
  83. ncbi request reprint Beta(2)-microglobulin as a negative growth regulator of myeloma cells
    Rui Min
    Myeloma and Transplantation Research Center, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA
    Br J Haematol 118:495-505. 2002
    ....
  84. ncbi request reprint Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning
    Ashraf Badros
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 20:1295-303. 2002
    ..We present our experience with relapsed and recently diagnosed patients with high-risk multiple myeloma (MM) receiving immunosuppressive, nonmyeloablative melphalan (MEL)-based conditioning regimens (mini-allograft)...
  85. ncbi request reprint Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer
    Gail Woods
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Cancer 110:830-4. 2007
    ..Galactomannan is an Aspergillus-specific antigen released during invasive aspergillosis and is detected by the quantitative serum galactomannan index (GMI) test...
  86. ncbi request reprint The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management
    Elias J Anaissie
    Myeloma Institute for Research and Therapy, The University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 103:1611-7. 2004
    ..RSV infection may not necessarily be a contraindication for APBSCT or an indication for therapy with aerosolized ribavirin and IVIG...
  87. doi request reprint Viability and engraftment of hematopoietic progenitor cells after long-term cryopreservation: effect of diagnosis and percentage dimethyl sulfoxide concentration
    Muthu Veeraputhiran
    Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    Cytotherapy 12:764-6. 2010
    ..8 years)...
  88. ncbi request reprint Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling
    Fenghuang Zhan
    Donna D and m Lambert Laboratory of Myeloma Genetics, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Semin Hematol 40:308-20. 2003
    ..Here we discuss recent progress made in the development of molecular-based diagnostics and prognostics for MM through the dissection of the transcriptome of PCs from healthy individuals and patients with MM and other PC dyscrasias...
  89. ncbi request reprint Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy
    Yue Jin Wen
    Myeloma and Transplantation Research Center, University of Arkansas for Medical Science, Little Rock 72205, USA
    Blood 99:3280-5. 2002
    ..These findings represent the first demonstration that tumor cell lysate-primed CTLs kill only myeloma cells, not autologous lymphocytes. This provides a rationale for myeloma cell-based immunotherapy in multiple myeloma...
  90. ncbi request reprint Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
    James R Berenson
    Cedars Sinai Medical Center and the Jonsson Comprehensive Cancer Center, University of California Los Angeles, USA
    Blood 99:3163-8. 2002
    ..Thus, 50 mg, oral, alternate-day prednisone is effective maintenance treatment for multiple myeloma patients who achieve a response to induction chemotherapy. (Blood. 2002;99:3163-3168)..
  91. ncbi request reprint A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience
    Joth L Jacobson
    Southwest Oncology Group Statistical Center, Seattle, WA 98101 1468, USA
    Br J Haematol 122:441-50. 2003
    ..Additional evaluation in other MM patient populations is needed to confirm results...
  92. ncbi request reprint Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial
    Paul G Richardson
    Department of Medical Oncology Hematologic Malignancies, Dana Farber Cancer Institute, Brigham and Women s Hospital, 44 Binney Street, Boston, MA 02115, USA
    Cancer 106:1316-9. 2006
    ..Bortezomib, a first-in-class proteasome inhibitor, has shown clinical activity in relapsed, refractory multiple myeloma in a pivotal Phase II trial, SUMMIT...
  93. ncbi request reprint Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
    Jeffrey Haessler
    Cancer Research and Biostatistics, Seattle, Washington, USA
    Clin Cancer Res 13:7073-9. 2007
    ..To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma...
  94. pmc Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells
    Unn Merete Fagerli
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, St Olavs University Hospital, Trondheim, Norway
    Blood 111:806-15. 2008
    ..In conclusion, PRL-3 is a gene product specifically expressed in malignant plasma cells and may have a role in migration of these cells...
  95. pmc High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis
    Frits van Rhee
    Blood 110:827-32. 2007
    ..65, P = .003). Unlike baseline and follow-up analyses of serum and urine M-proteins, high SFLC levels at baseline-reflecting more aggressive disease-and steeper reductions after therapy identified patients with inferior survival...
  96. ncbi request reprint Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma
    Shigeyuki Matsui
    Department of Pharmacoepidemiology, School of Public Health, Kyoto University, Yoshida konoe cho, Sakyo ku, Kyoto, Japan
    Stat Med 27:1106-20. 2008
    ..Application of such clustering to the data set from a clinical study for patients with multiple myeloma and associated microarrays is given...
  97. pmc Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
    Sagar Lonial
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Blood 106:3777-84. 2005
    ..The exact mechanism underlying bortezomib-induced thrombocytopenia remains unknown but it is unlikely to be related to marrow injury or decreased thrombopoietin production...
  98. pmc High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone
    Fenghuang Zhan
    Blood 111:968-9. 2008
  99. doi request reprint Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy
    Guido Tricot
    University of Utah School of Medicine, 30N 1900E, 5C402, Salt Lake City, UT 84132 USA
    Haematologica 93:1739-42. 2008
    ..001) and (v) platelet recovery was faster after first transplant (when less stem cells were infused) (p=0.01). Pegfilgrastim may be considered the standard of care for stem cell mobilization...
  100. pmc Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma
    Bart Burington
    Cancer Research and Biostatistics, Seattle, Washington, USA
    Clin Cancer Res 14:4821-9. 2008
    ..Genes whose drug-altered expression were found to be related to survival may point to molecular switches related to response and/or resistance to different classes of drugs...
  101. ncbi request reprint Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival
    Kai Da Wu
    Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 101:4982-9. 2003
    ..004). The 2-year survival rate for patients with TA levels lower than 25% was 81%, and it was 52% in those with higher TA levels (P <.0001)...